Influence of experimentally induced toxoplasmosis (Toxoplasma gondii) on the pharmacokinetics of levofloxacin

Bulletin of the Veterinary Institute in Pulawy

Volumn 47, Issue 2, 2003, Pages 479-485

  Yarsan, Ender ^a   Tanyuksel, Mehmet ^b   Koc, Feride ^c   Essiz, Dinc ^a   Babur, Cahit ^d  

^a ANKARA UNIVERSITY   (Turkey)

^b GULHANE SCHOOL OF MEDICINE   (Turkey)

^c Central Veterinary Control and Research Institute   (Turkey)

^d Refik Saydam Natl Inst Hlth C   (Turkey)

Author keywords

Levofloxacin; Mice; Pharmacokinetics; T. gondii

Indexed keywords

LEVOFLOXACIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG HALF LIFE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MOUSE; NONHUMAN; PROTOZOON; TOXOPLASMA GONDII; TOXOPLASMOSIS; TROPHOZOITE;

ANIMALIA; BACTERIA (MICROORGANISMS); PROTOZOA; TOXOPLASMA GONDII;

EID: 1442359739     PISSN: 00424870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. th Ed. Iowa State University Press, Ames, 1998.
2. Cambell W.C., Rew R.S.: Chemotherapy of parasitic diseases. Plenum Press, New York, 1986.
3. Child J., Motiboy D., Andrews J.M., Chow A.T., Wise R.: Open-label crossover study to determine the pharmacokinetics and penetration of two dose regimens of levofloxacin into inflammatory fluid. Antimicrob. Agents Chemother., 1995, 39, 2749-2751.
4. Davis R., Bryson H.M.: Levofloxacin: A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy. Drugs, 1994, 47, 677-700.
5. Dubey J.P., Beattie C.P.: Toxoplasmosis of Animals and Man. CRC Press, Inc. Boca Raton-Florida, 1988.
6. Fernandez J., Barrett J.F., Licata L., Frosco M.: Comparison of efficacies of oral levofloxacin and oral ciprofloxacin in a rabbit model of a staphylococcal abscess. Antimicrob. Agents Chemother., 1999, 43, 667-671.
7. Fish D.N., Chow A.T.: The clinical pharmacokinetics of levofloxacin. Clin Pharmacokinet., 1997, 32, 101-119.
8. Fraser C.M., Bergeron J.A., Mays A., Aiella S.E.: The Merck Veterinary Manual. Merck. Co, Inc. Rahway, N.J. USA, 1991.
9. Gigogos P.G., Reversado P.R., Cadahia O., Fente C.A., Vazaquez B.I., Franco C.M., Cepeda A.: Determination of quinolones in animal tissues and eggs by HPLC with photodiode-array detection. J. Chromatog. A., 2000, 871, 31-36.
10. Goodwin S.D., Gallis H.A., Chow A.T., Wong F.A., Flor S.C., Bartlett J.A.: Pharmacokinetics and safety of levofloxacin in patients with human immunodeficiency virus infections. Antimicrob. Agents Chemother., 1994, 38, 799-804.
11. Hooper D.C., Wolfson J.S.: Fluoroquinolone antimicrobial agents. N. E. J. M., 1991, 324, 384-394.
12. Hooper D.C., Wolfson J.S.: The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans. Antimicrob. Agents Chemother., 1985, 28, 716-721.
13. Lu Y., Zhu L., Duan L.: Antituberculosis effect of levofloxacin. Zhonghua, 2000, 23, 50-54.
14. Nakamori Y., Tsuboi E., Narui K., Nakatani T., Nakata K., Sugi H.: Sputum penetration of levofloxacin and its clinical efficacy in patients with chronic lower respiratory tracts infections. Jpn. J. Antibiot., 1992, 45, 539-547.
15. North D.S., Fish D.N., Redington J.J.: Levofloxacin a second-generation fluoroquinolone. Pharmacotherapy, 1998, 18, 915-935.
16. Onyeji C.O., Bui K.Q., Owens R.C., Nicolau D.P., Quintiliani R., Nightingale C.H.: Comparative efficacies of levofloxacin and ciprofloxacin against streptococcus pneumonia in a mouse model of experimental septicemia. Int. J. Antimicrob. Agents, 1999, 12, 107-114.
17. Preston S.L., Drusano G.L., Berman A.L., Fowler C.L., Chow A.T., Dornseif B., Reichl V., Natarajan J., Wong F.A., Corrado M.: Levofloxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infection. Antimicrob. Agents Chemother., 1998, 42, 1098-1104
18. th International Symposium on New Quinolones. Singapore, 1994.
19. Saito A., Aguchi K., Harada T.: Pharmacokinetic of levofloxacin in patients with impaired renal function. Chemotherapy, 1992, 40, 188-195.
20. Tunaka K.I., Iwamoto M., Maesaki S., Koga H., Kohno S., Hara K., Sugawara K., Kaku M. Kusano S., Sakito O.: Basic and clinical studies on respiratory infections. Jpn. J. Antibiot., 1992, 45, 548-555.
21. Wagner J.G.: Fundamentals of clinical pharmacokinetics. Drug Intelligence Pub. Inc., Chicago, 1975.
22. Wimer S.M., Schoonarer L., Garrison M.W.: Levofloxacin: A therapeutic review. Clin. Therapeutics, 1998, 20, 1049-1065.